89Sr therapy for pain relief in patients with bone metastases

Kiyoshi Koizumi; Ali S. Arbab; Keiji Toyama; Masayo Shirasu; Sachiko Osawa; Takuji Araki; Motoshi Yamaguchi; Hiroshi Onishi; Tsutomu Araki; Takao Arai; Hideki Komatsu; Akira Ueno; Hisashi Nokata

⁸⁹Sr therapy for pain relief in patients with bone metastases

Kiyoshi Koizumi, Ali S. Arbab, Keiji Toyama, Masayo Shirasu, Sachiko Osawa, Takuji Araki, Motoshi Yamaguchi, Hiroshi Onishi, Tsutomu Araki, Takao Arai, Hideki Komatsu, Akira Ueno, Hisashi Nokata

Research output: Contribution to journal › Article › peer-review

Abstract

Radioactive strontium chloride ( ⁸⁹Sr) was administered for pain relief in 6 patients with bone metastases (4 prostate cancer and 2 breast cancer patients). Out of 6 patients, 2 showed apparent relief of bone pain and improvement of QOL, and 3 showed slight relief of the pain with or without improvement of QOL; that is, 83% was effective. Side effects were seen in 2 patients; transient deterioration of bone pain in one patient and bone marrow suppression in the other patient. The patient who showed bone marrow suppression had rather more lesions of bone metastasis (diffuse metastasis) and least urinary excretion of the radioactivity. Urinary excretion for 2 days varied 5 to 40% of the administered dose and was less in the patients with more metastatic lesions.

Original language	English (US)
Pages (from-to)	1243-1248
Number of pages	6
Journal	Kakuigaku
Volume	33
Issue number	11
State	Published - 1996
Externally published	Yes

Keywords

Bone metastasis
Pain relief
Radionuclide therapy
Sr

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Cite this

@article{7d193c4d590c41a79ae99cc51537f550,

title = "89Sr therapy for pain relief in patients with bone metastases",

abstract = "Radioactive strontium chloride ( 89Sr) was administered for pain relief in 6 patients with bone metastases (4 prostate cancer and 2 breast cancer patients). Out of 6 patients, 2 showed apparent relief of bone pain and improvement of QOL, and 3 showed slight relief of the pain with or without improvement of QOL; that is, 83% was effective. Side effects were seen in 2 patients; transient deterioration of bone pain in one patient and bone marrow suppression in the other patient. The patient who showed bone marrow suppression had rather more lesions of bone metastasis (diffuse metastasis) and least urinary excretion of the radioactivity. Urinary excretion for 2 days varied 5 to 40% of the administered dose and was less in the patients with more metastatic lesions.",

keywords = "Bone metastasis, Pain relief, Radionuclide therapy, Sr",

author = "Kiyoshi Koizumi and Arbab, {Ali S.} and Keiji Toyama and Masayo Shirasu and Sachiko Osawa and Takuji Araki and Motoshi Yamaguchi and Hiroshi Onishi and Tsutomu Araki and Takao Arai and Hideki Komatsu and Akira Ueno and Hisashi Nokata",

year = "1996",

language = "English (US)",

volume = "33",

pages = "1243--1248",

journal = "Kaku igaku. The Japanese journal of nuclear medicine",

issn = "0022-7854",

publisher = "Japanese Society of Nuclear Medicine",

number = "11",

}

TY - JOUR

T1 - 89Sr therapy for pain relief in patients with bone metastases

AU - Koizumi, Kiyoshi

AU - Arbab, Ali S.

AU - Toyama, Keiji

AU - Shirasu, Masayo

AU - Osawa, Sachiko

AU - Araki, Takuji

AU - Yamaguchi, Motoshi

AU - Onishi, Hiroshi

AU - Araki, Tsutomu

AU - Arai, Takao

AU - Komatsu, Hideki

AU - Ueno, Akira

AU - Nokata, Hisashi

PY - 1996

Y1 - 1996

N2 - Radioactive strontium chloride ( 89Sr) was administered for pain relief in 6 patients with bone metastases (4 prostate cancer and 2 breast cancer patients). Out of 6 patients, 2 showed apparent relief of bone pain and improvement of QOL, and 3 showed slight relief of the pain with or without improvement of QOL; that is, 83% was effective. Side effects were seen in 2 patients; transient deterioration of bone pain in one patient and bone marrow suppression in the other patient. The patient who showed bone marrow suppression had rather more lesions of bone metastasis (diffuse metastasis) and least urinary excretion of the radioactivity. Urinary excretion for 2 days varied 5 to 40% of the administered dose and was less in the patients with more metastatic lesions.

AB - Radioactive strontium chloride ( 89Sr) was administered for pain relief in 6 patients with bone metastases (4 prostate cancer and 2 breast cancer patients). Out of 6 patients, 2 showed apparent relief of bone pain and improvement of QOL, and 3 showed slight relief of the pain with or without improvement of QOL; that is, 83% was effective. Side effects were seen in 2 patients; transient deterioration of bone pain in one patient and bone marrow suppression in the other patient. The patient who showed bone marrow suppression had rather more lesions of bone metastasis (diffuse metastasis) and least urinary excretion of the radioactivity. Urinary excretion for 2 days varied 5 to 40% of the administered dose and was less in the patients with more metastatic lesions.

KW - Bone metastasis

KW - Pain relief

KW - Radionuclide therapy

KW - Sr

UR - http://www.scopus.com/inward/record.url?scp=0030299789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030299789&partnerID=8YFLogxK

M3 - Article

C2 - 8986064

AN - SCOPUS:0030299789

VL - 33

SP - 1243

EP - 1248

JO - Kaku igaku. The Japanese journal of nuclear medicine

JF - Kaku igaku. The Japanese journal of nuclear medicine

SN - 0022-7854

IS - 11

ER -

⁸⁹Sr therapy for pain relief in patients with bone metastases

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this